Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Authors' Reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Assessment of Perfusion and Oxygenation of the Human Renal Cortex and Medulla by Quantitative MRI during Handgrip Exercise

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Iatrogen botulisme ved terapeutisk brug af botulinumtoksin

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Recommendations from the EXTRIP workgroup on extracorporeal treatment for baclofen poisoning

    Publikation: Bidrag til tidsskriftLederForskningpeer review

Vis graf over relationer

BACKGROUND: Although chloroquine, hydroxychloroquine, and quinine are used for a range of medical conditions, recent research suggested a potential role in treating COVID-19. The resultant increase in prescribing was accompanied by an increase in adverse events, including severe toxicity and death. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup sought to determine the effect of and indications for extracorporeal treatments in cases of poisoning with these drugs.

METHODS: We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.

RESULTS: A total of 44 studies (three in vitro studies, two animal studies, 28 patient reports or patient series, and 11 pharmacokinetic studies) met inclusion criteria regarding the effect of extracorporeal treatments. Toxicokinetic or pharmacokinetic analysis was available for 61 patients (13 chloroquine, three hydroxychloroquine, and 45 quinine). Clinical data were available for analysis from 38 patients, including 12 with chloroquine toxicity, one with hydroxychloroquine toxicity, and 25 with quinine toxicity. All three drugs were classified as non-dialyzable (not amenable to clinically significant removal by extracorporeal treatments). The available data do not support using extracorporeal treatments in addition to standard care for patients severely poisoned with either chloroquine or quinine (strong recommendation, very low quality of evidence). Although hydroxychloroquine was assessed as being non-dialyzable, the clinical evidence was not sufficient to support a formal recommendation regarding the use of extracorporeal treatments for this drug.

CONCLUSIONS: On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning.

OriginalsprogEngelsk
TidsskriftJournal of the American Society of Nephrology : JASN
Vol/bind31
Udgave nummer10
Sider (fra-til)2475-2489
Antal sider15
ISSN1046-6673
DOI
StatusUdgivet - okt. 2020

Bibliografisk note

Copyright © 2020 by the American Society of Nephrology.

ID: 62362738